Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2021
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
802
-100.0%
|
$265,462
$331.15 P/Share
|
|
Jun 18
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
1,156
-100.0%
|
$381,480
$330.93 P/Share
|
|
Jun 16
2021
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Jingshyh S Su Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Thomas Malley Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+31.35%
|
-
|
|
Jun 16
2021
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Donald W. Glazer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+0.28%
|
-
|
|
Jun 16
2021
|
Timothy Yung Cheng Chen Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
25,350
+7.69%
|
-
|
|
Jun 16
2021
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
53,625
+18.35%
|
-
|
|
Jun 16
2021
|
Xiaobin Wu President, COO & GM China |
BUY
Grant, award, or other acquisition
|
Direct |
78,000
+6.04%
|
-
|
|
Jun 16
2021
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+0.67%
|
-
|
|
Jun 16
2021
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
146,250
+2.06%
|
-
|
|
Jun 16
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
31,200
+31.33%
|
-
|
|
Jun 10
2021
|
Timothy Yung Cheng Chen Director |
SELL
Open market or private sale
|
Direct |
2,836
-57.29%
|
$998,272
$352.07 P/Share
|
|
Jun 10
2021
|
Timothy Yung Cheng Chen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,836
+50.0%
|
$87,916
$31.59 P/Share
|
|
Jun 09
2021
|
Timothy Yung Cheng Chen Director |
SELL
Open market or private sale
|
Direct |
3,164
-69.92%
|
$1,110,564
$351.62 P/Share
|
|
Jun 09
2021
|
Timothy Yung Cheng Chen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,164
+50.0%
|
$98,084
$31.59 P/Share
|
|
Jun 07
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
603
-100.0%
|
$211,653
$351.55 P/Share
|
|
Jun 07
2021
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
656
-100.0%
|
$232,224
$354.26 P/Share
|
|
Jun 07
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
650
-100.0%
|
$230,100
$354.16 P/Share
|
|
Jun 07
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
3,398
-94.26%
|
$1,196,096
$352.48 P/Share
|
|
Jun 03
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
7,400
-0.27%
|
-
|
|
Jun 01
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
69,000
-2.44%
|
-
|
|
Jun 01
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
540
-100.0%
|
$195,480
$362.64 P/Share
|
|
May 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
540
+50.0%
|
-
|
|
May 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
7,189
+2.4%
|
-
|
|
May 28
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-49.01%
|
$534,000
$356.55 P/Share
|
|
May 28
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
May 27
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
4,700
-0.17%
|
-
|
|
May 10
2021
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
3,394
-61.58%
|
$1,021,594
$301.23 P/Share
|
|
May 10
2021
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,394
+50.0%
|
$0
$0.13 P/Share
|
|
May 10
2021
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
44,109
+0.76%
|
$0
$0.13 P/Share
|
|
May 03
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
6,715
-100.0%
|
$2,303,245
$343.0 P/Share
|
|
Apr 29
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-41.73%
|
$531,000
$354.48 P/Share
|
|
Apr 29
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Mar 29
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-49.34%
|
$486,000
$324.25 P/Share
|
|
Mar 29
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Mar 12
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
80,000
-2.75%
|
-
|
|
Feb 26
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-35.38%
|
$478,500
$319.27 P/Share
|
|
Feb 26
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Jan 29
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-33.68%
|
$486,000
$324.17 P/Share
|
|
Jan 29
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Jan 15
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
12,600
-77.75%
|
$4,334,400
$344.96 P/Share
|
|
Jan 15
2021
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+50.0%
|
$75,600
$6.5 P/Share
|
|
Jan 14
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,400
-89.29%
|
$481,600
$344.71 P/Share
|
|
Jan 14
2021
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+50.0%
|
$8,400
$6.5 P/Share
|
|
Jan 04
2021
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
121,154
-1.03%
|
$26,653,880
$220.5 P/Share
|
|
Dec 29
2020
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-38.57%
|
$372,000
$248.87 P/Share
|